Intuitive Surgical Drops 14% as Procedure Growth Cools After a Q2 Beat

Intuitive Surgical (ISRG) fell 14.1% on Friday to close at $345.42, a day after the maker of da Vinci robotic-surgery systems reported second-quarter results that cleared Wall Street’s estimates on both revenue and profit. The reaction centered on one number the beat did not fix: how fast surgeons are actually using its machines. The headline figures were not the story.

Procedure growth slipped to the low teens

After Thursday’s close, Intuitive said second-quarter revenue rose 19% from a year earlier to $2.89 billion, ahead of the $2.82 billion analysts had modeled. Adjusted earnings of $2.80 per share topped the $2.50 consensus by 12%, and GAAP net income came to $818 million, or $2.29 a diluted share. Worldwide procedures across the da Vinci and Ion platforms grew about 16% year over year, and the company placed 468 da Vinci systems in the quarter, up from 395 a year earlier.

The problem sat in the trend. Management said U.S. da Vinci procedure growth eased to 12% in the quarter from 14% in the first, and it held its full-year worldwide procedure forecast at 13.5% to 15.5%, saying it expects to finish closer to the midpoint. It left that range untouched despite a strong first half. Executives tied the softening to weaker demand for elective operations amid uncertainty over changes to Affordable Care Act premium subsidies, and to a continued high-single-digit decline in bariatric procedures as GLP-1 weight-loss drugs displace surgery. They also flagged tougher year-over-year comparisons in the second half.

For a stock priced on the durability of that growth, a decelerating procedure count carried more weight than the headline beat. Shares had already dropped 8.5% in Thursday’s extended session before the selling deepened through Friday.

A third off its spring high

Friday’s move extended a rough stretch. ISRG had already fallen about 17% over the prior 30 days, and the close left it 30% below its 90-day high of $493.56 and below its lowest close of the previous three months. Volume told the same story. Some 11.6 million shares changed hands, nearly four times the stock’s 20-day average of 2.96 million.

The broader medical-device group did not move with it in any comparable way; the selling was specific to the reset in Intuitive’s growth outlook rather than a sector event. That distinction matters for a company whose valuation has long rested on procedure volumes compounding well into the double digits.

The midpoint the company is defending

The full-year target of 13.5% to 15.5%, with results expected closer to the midpoint, is the benchmark against which the next two quarters will be read. That makes second-half U.S. da Vinci volumes the figure to track, set against the tougher comparisons management flagged and the unresolved questions over ACA subsidy changes.

System placements cut the other way. Intuitive installed 246 of its newest da Vinci 5 units in the quarter, more than half of its da Vinci total, and that growing installed base feeds directly into future procedure capacity. Whether hospitals keep buying at that clip while elective demand softens is the tension the company now has to manage in the open.

This is a general-market summary for information only — not investment advice, and not a recommendation regarding any security.